Interview with the Innovators

PYLARIFY Imaging in High-Risk Prostate Cancer

Video Library —February 1, 2022
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Related Articles
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, Emily Beard, RN, BSN, OCN, CBCN
|
Video Library
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
How Well Do Patients Tolerate Ovarian Function Suppression? Oncology Nurse Navigators Discuss Their Experience
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
This Interview with the Innovator video features breast cancer nurse navigators Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, as they discuss ovarian function suppression, how patients tolerate side effects, and educating patients on expectations of treatment.
Ovarian Suppression: What Are Some of the Important Questions That Women Ask?
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country